Our data are consistent with reports showing that suppression of either mPGES-1 or EP-4 expression reduces AAA development in animal models [15, 21, 22] and reinforce the potential of mPGES-1 and EP-4 as alternative targets for therapy in AAA patients. Here, PTGER4 is linked to triple-A syndrome.